UA110525C2 - Похідні піразолу - Google Patents
Похідні піразолуInfo
- Publication number
- UA110525C2 UA110525C2 UAA201400123A UAA201400123A UA110525C2 UA 110525 C2 UA110525 C2 UA 110525C2 UA A201400123 A UAA201400123 A UA A201400123A UA A201400123 A UAA201400123 A UA A201400123A UA 110525 C2 UA110525 C2 UA 110525C2
- Authority
- UA
- Ukraine
- Prior art keywords
- halogen
- deputy
- yak
- disorders
- disruption
- Prior art date
Links
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000006467 substitution reaction Methods 0.000 abstract 2
- 241001279686 Allium moly Species 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 102000011829 Trace amine associated receptor Human genes 0.000 abstract 1
- 108050002178 Trace amine associated receptor Proteins 0.000 abstract 1
- 230000001133 acceleration Effects 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 239000003513 alkali Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000003749 cleanliness Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 230000013632 homeostatic process Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Даний винахід стосується сполук формулидеRозначає водень або феніл, який, можливо, містить як замісник галоген, CN чи нижчу алкоксигрупу, або ж нижчу алкоксигрупу, заміщену галогеном;Rозначає водень або нижчий алкіл;Rозначає водень або нижчий алкіл або означає феніл, який, можливо, містить один чи декілька замісників, вибраних з такого: галоген, ціаногрупа чи нижча алкоксигрупа, заміщена галогеном, або означаєпіридиніл, який, можливо, містить як замісник галоген або нижчий алкіл, заміщений галогеном, або означаєпіримідиніл, який, можливо, містить як замісник нижчий алкіл, заміщений галогеном, або означаєпіразиніл, який, можливо, містить як замісник галоген, ціаногрупу або нижчий алкіл, заміщений галогеном;Rозначає водень, нижчий алкіл або феніл;Ζ означає зв'язок, -СН- або -О-;або її фармацевтично прийнятні кислотно-адитивні солі.Було показано, що сполуки формул ІА та IB мають високу спорідненість відносно рецепторів слідових амінів (TAARs), зокрема TAAR1.Ці сполуки можна застосовувати для лікування депресії, тривожного неврозу, біполярного розладу, синдрому дефіциту уваги та гіперактивності (СДУГ), розладів, пов'язаних зі стресом, психічних розладів, таких як шизофренія, неврологічних захворювань, таких як хвороба Паркінсона, нейродегенеративних розладів, таких як хвороба Альцгеймера, епілепсії, мігрені, гіпертонії, наркотичної залежності та токсикоманії та метаболічних розладів, таких як розлади приймання їжі, діабету, діабетичних ускладнень, тучності, дисліпідемії, розладів споживання та засвоєння енергії, розладів та порушень функції гомеостазу температури тіла, розладів сну та добового біоритму та серцево-судинних захворювань.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11169217 | 2011-06-09 | ||
| PCT/EP2012/060627 WO2012168260A1 (en) | 2011-06-09 | 2012-06-06 | Pyrazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA110525C2 true UA110525C2 (ru) | 2016-01-12 |
Family
ID=46298390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201400123A UA110525C2 (ru) | 2011-06-09 | 2012-06-06 | Похідні піразолу |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9073911B2 (ru) |
| EP (1) | EP2717873B1 (ru) |
| JP (1) | JP5914642B2 (ru) |
| KR (1) | KR101574905B1 (ru) |
| CN (1) | CN103596567B (ru) |
| AR (1) | AR088741A1 (ru) |
| AU (1) | AU2012266457B2 (ru) |
| BR (1) | BR112013031324B1 (ru) |
| CA (1) | CA2837255C (ru) |
| CL (1) | CL2013003484A1 (ru) |
| CO (1) | CO6801764A2 (ru) |
| CY (1) | CY1116778T1 (ru) |
| DK (1) | DK2717873T3 (ru) |
| EA (1) | EA024648B1 (ru) |
| EC (1) | ECSP13013072A (ru) |
| ES (1) | ES2546438T3 (ru) |
| HR (1) | HRP20151077T1 (ru) |
| IL (1) | IL229549B (ru) |
| MA (1) | MA35192B1 (ru) |
| MX (1) | MX347239B (ru) |
| MY (1) | MY162160A (ru) |
| PE (1) | PE20140934A1 (ru) |
| PH (1) | PH12013502315A1 (ru) |
| PL (1) | PL2717873T3 (ru) |
| PT (1) | PT2717873E (ru) |
| RS (1) | RS54183B1 (ru) |
| SG (1) | SG195156A1 (ru) |
| SI (1) | SI2717873T1 (ru) |
| TW (1) | TWI440636B (ru) |
| UA (1) | UA110525C2 (ru) |
| WO (1) | WO2012168260A1 (ru) |
| ZA (1) | ZA201308939B (ru) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9029370B2 (en) | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
| EP2802578B1 (en) * | 2012-01-12 | 2015-10-07 | F.Hoffmann-La Roche Ag | Heterocyclic derivatives as trace amine associated receptors (taars) |
| ES2654653T3 (es) * | 2012-09-14 | 2018-02-14 | F. Hoffmann-La Roche Ag | Derivados de pirazol-carboxamida como moduladores de TAAR para su uso en el tratamiento de varios trastornos, tales como depresión, diabetes y enfermedad de Parkinson |
| EP2928473B1 (en) * | 2012-12-07 | 2017-06-28 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
| WO2015165085A1 (en) * | 2014-04-30 | 2015-11-05 | F.Hoffmann-La Roche Ag | Morpholin-pyridine derivatives |
| PE20181446A1 (es) * | 2016-03-17 | 2018-09-12 | Hoffmann La Roche | Derivados de 5-etil-4-metil-pirazol-3-carboxamida con actividad como de taar |
| SG11201909807TA (en) | 2017-04-24 | 2019-11-28 | Tesaro Inc | Methods of manufacturing of niraparib |
| CN112480079B (zh) * | 2017-11-08 | 2022-03-11 | 北京嘉林药业股份有限公司 | 化合物及其治疗癌症的用途 |
| JP7296408B2 (ja) * | 2018-06-18 | 2023-06-22 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤としてのピラゾール誘導体 |
| KR102161787B1 (ko) * | 2018-07-02 | 2020-10-06 | 한국기초과학지원연구원 | 수면 장애의 예방 또는 치료용 약학적 조성물 |
| WO2020064792A1 (en) | 2018-09-27 | 2020-04-02 | F. Hoffmann-La Roche Ag | Heterocyclyl compounds for the treatment of autoimmune disease |
| KR102396602B1 (ko) * | 2019-02-28 | 2022-05-11 | 주식회사 마더스제약 | 피라졸 아마이드 유도체 화합물 및 이의 용도 |
| BR112021022977A2 (pt) * | 2019-05-14 | 2022-01-04 | Metabomed Ltd | Compostos inibidores acss2 e métodos para uso dos mesmos |
| CA3146830A1 (en) * | 2019-07-11 | 2021-01-14 | F. Hoffmann-La Roche Ag | Process for the preparation of substituted pyrazole derivatives |
| WO2023283369A1 (en) * | 2021-07-08 | 2023-01-12 | Vibliome Therapeutics, Llc | Modulators of protein kinases |
| WO2023183444A1 (en) * | 2022-03-24 | 2023-09-28 | Vibliome Therapeutics, Llc | Modulators of protein kinases |
| KR20250044870A (ko) * | 2022-08-12 | 2025-04-01 | 에프. 호프만-라 로슈 아게 | 5-에틸-4-메틸-n-[4-[(2s) 모르폴린-2-일]페닐]-1h-피라졸-3-카르복스아미드를 포함하는 약제학적 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9425211D0 (en) | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| GB9520150D0 (en) | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| IL136388A0 (en) | 1997-12-04 | 2001-06-14 | Allergan Sales Inc | Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors |
| US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| MX2009008465A (es) | 2007-02-15 | 2009-08-20 | Hoffmann La Roche | Nuevas 2-aminooxazolinas como ligandos de taar1. |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| US9132136B2 (en) * | 2010-08-02 | 2015-09-15 | Hoffmann-La Roche Inc. | Pharmaceutical combination |
| US9029370B2 (en) | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
| CN102899314A (zh) | 2011-07-29 | 2013-01-30 | 江汉大学 | 一种批量基因克隆的方法 |
-
2012
- 2012-06-01 US US13/485,969 patent/US9073911B2/en active Active
- 2012-06-06 MX MX2013013853A patent/MX347239B/es active IP Right Grant
- 2012-06-06 ES ES12727632.7T patent/ES2546438T3/es active Active
- 2012-06-06 WO PCT/EP2012/060627 patent/WO2012168260A1/en not_active Ceased
- 2012-06-06 PH PH1/2013/502315A patent/PH12013502315A1/en unknown
- 2012-06-06 PE PE2013002748A patent/PE20140934A1/es active IP Right Grant
- 2012-06-06 TW TW101120350A patent/TWI440636B/zh not_active IP Right Cessation
- 2012-06-06 KR KR1020147000462A patent/KR101574905B1/ko not_active Expired - Fee Related
- 2012-06-06 RS RS20150549A patent/RS54183B1/sr unknown
- 2012-06-06 PL PL12727632T patent/PL2717873T3/pl unknown
- 2012-06-06 CN CN201280027873.0A patent/CN103596567B/zh not_active Expired - Fee Related
- 2012-06-06 JP JP2014514042A patent/JP5914642B2/ja not_active Expired - Fee Related
- 2012-06-06 MY MYPI2013004400A patent/MY162160A/en unknown
- 2012-06-06 SG SG2013087234A patent/SG195156A1/en unknown
- 2012-06-06 DK DK12727632.7T patent/DK2717873T3/en active
- 2012-06-06 SI SI201230279T patent/SI2717873T1/sl unknown
- 2012-06-06 UA UAA201400123A patent/UA110525C2/ru unknown
- 2012-06-06 AU AU2012266457A patent/AU2012266457B2/en not_active Ceased
- 2012-06-06 CA CA2837255A patent/CA2837255C/en active Active
- 2012-06-06 EP EP12727632.7A patent/EP2717873B1/en active Active
- 2012-06-06 PT PT127276327T patent/PT2717873E/pt unknown
- 2012-06-06 BR BR112013031324-2A patent/BR112013031324B1/pt not_active IP Right Cessation
- 2012-06-06 HR HRP20151077TT patent/HRP20151077T1/hr unknown
- 2012-06-06 EA EA201391787A patent/EA024648B1/ru not_active IP Right Cessation
- 2012-06-07 AR ARP120102009A patent/AR088741A1/es unknown
-
2013
- 2013-10-31 CO CO13258855A patent/CO6801764A2/es active IP Right Grant
- 2013-11-21 IL IL229549A patent/IL229549B/en active IP Right Grant
- 2013-11-27 ZA ZA2013/08939A patent/ZA201308939B/en unknown
- 2013-12-05 CL CL2013003484A patent/CL2013003484A1/es unknown
- 2013-12-09 EC ECSP13013072 patent/ECSP13013072A/es unknown
- 2013-12-18 MA MA36583A patent/MA35192B1/fr unknown
-
2015
- 2015-10-06 CY CY20151100893T patent/CY1116778T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA110525C2 (ru) | Похідні піразолу | |
| ECSP12012098A (es) | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos | |
| AR079542A1 (es) | Derivados de benzamida sustituidos, proceso para su preparacion y su uso en el tratamiento de enfermedades mediadas por taars. | |
| UA112317C2 (uk) | Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину | |
| PH12015501072A1 (en) | Novel pyrazine derivatives as cb2 receptor agonists | |
| MY169479A (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| MX361457B (es) | Sulfonamidas que contienen carbazol como moduladoras de criptocromo. | |
| ECSP13012896A (es) | Derivados heterocíclicos de amina | |
| MX361761B (es) | Derivados de triazol carboxamida. | |
| MX2012007582A (es) | Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida. | |
| MX354410B (es) | Derivados de benzamida sustituida. | |
| MX2013011124A (es) | Compuestos para el tratamiento del sindrome metabolico. | |
| MX350862B (es) | Acidos de piperidinil naftilacetico. | |
| NZ705144A (en) | Ethynyl derivatives as modulators of mglur5 receptor activity | |
| MX2016016488A (es) | Derivados de azetidina sustituidos como ligandos de receptores asociados a aminas en trazas (taar). | |
| MX354815B (es) | Derivados heterociclicos como receptores asociados con las aminas traza (taars). | |
| PE20090999A1 (es) | Nuevos derivados de metil-bencimidazol | |
| PH12015500489B1 (en) | Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease | |
| IL206615A0 (en) | Piperidine sulfonamide derivatives | |
| MX2012001799A (es) | Derivados de pirrolidina como antagonistas del receptor de neuroquinona 3 (nk3). | |
| MY181847A (en) | Ethynyl derivatives as metabotropic glutamate receptor antagonists | |
| BR112013010558A2 (pt) | derivados de di-hidro-oxazol-2-amina | |
| EA201270799A1 (ru) | Новые спирогетероциклические соединения и их применение в качестве антагонистов mglu5 | |
| BR112014006675A2 (pt) | derivados de metanossulfonamida substituídos como ligantes de receptor vaniloide | |
| MX2014003455A (es) | Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide. |